Akèy › Limfòm folikilè › Illinois › Chicago
Etid klinik pou Limfòm folikilè nan Chicago, IL
12 etid pou Limfòm folikilè ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Ap rekriteFaz 3
- University of Illinois, Chicago
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Ap rekriteFaz 1/2
- Northwestern Memorial Hospital, Chicago
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Chicago
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Ap rekriteFaz 1
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Ap rekriteFaz 3
- University of Chicago, Chicago
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Ap rekriteFaz 2
- Ruth M. Rothstein CORE Center, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Northwestern University, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- The University of Chicago Medical Center, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Northwestern Memorial Hospital, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Etid Limfòm folikilè nan lòt vil
- New York City, NY24 etid
- Milwaukee, WI19 etid
- Nashville, TN18 etid
- Houston, TX18 etid
- Boston, MA17 etid
- Baldwin Park, CA16 etid
- Seattle, WA15 etid
- Durham, NC15 etid
- Columbus, OH13 etid
- Salt Lake City, UT13 etid
- San Antonio, TX12 etid
- Philadelphia, PA12 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.